663 related articles for article (PubMed ID: 26003033)
21. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
22. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.
Doyle LA; Sepehr GJ; Hamilton MJ; Akin C; Castells MC; Hornick JL
Am J Surg Pathol; 2014 Jun; 38(6):832-43. PubMed ID: 24618605
[TBL] [Abstract][Full Text] [Related]
23. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis.
Kurosawa M; Amano H; Kanbe N; Akimoto S; Takeuchi Y; Yamashita T; Hashimoto T; Kurimoto F; Miyachi Y
J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 2):S25-32. PubMed ID: 9440541
[TBL] [Abstract][Full Text] [Related]
25. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
26. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
27. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
Horny HP; Sotlar K; Valent P
Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
[TBL] [Abstract][Full Text] [Related]
28. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
29. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
30. An Unusual Transition from Cutaneous to Systemic Mastocytosis in a Pediatric Patient.
Patel K; Cuervo-Pardo L; Cresoe S; Cavero-Chavez V
Pediatr Allergy Immunol Pulmonol; 2023 Dec; 36(4):150-152. PubMed ID: 38134319
[No Abstract] [Full Text] [Related]
31. Current approaches to the diagnosis and treatment of systemic mastocytosis.
Bains SN; Hsieh FH
Ann Allergy Asthma Immunol; 2010 Jan; 104(1):1-10; quiz 10-2, 41. PubMed ID: 20143640
[TBL] [Abstract][Full Text] [Related]
32. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
33. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.
Alvarez-Twose I; González-de-Olano D; Sánchez-Muñoz L; Matito A; Jara-Acevedo M; Teodosio C; García-Montero A; Morgado JM; Orfao A; Escribano L
Int Arch Allergy Immunol; 2012; 157(3):275-80. PubMed ID: 22042301
[TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre.
Hermans MAW; Rietveld MJA; van Laar JAM; Dalm VASH; Verburg M; Pasmans SGMA; Gerth van Wijk R; van Hagen PM; van Daele PLA
Eur J Intern Med; 2016 May; 30():25-30. PubMed ID: 26809706
[TBL] [Abstract][Full Text] [Related]
35. Mastocytosis: a comprehensive insight.
VAN Gysel D; DE Maeseneer H; Oranje AP
G Ital Dermatol Venereol; 2016 Aug; 151(4):385-96. PubMed ID: 27070304
[TBL] [Abstract][Full Text] [Related]
36. Systemic mastocytosis: current concepts and treatment advances.
Tefferi A; Pardanani A
Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
[TBL] [Abstract][Full Text] [Related]
37. Exophthalmos, Diplopia, and Bilateral Eyelid Edema: Symptoms of Ocular Mastocytosis.
Payerols A; Frouin E; Schiffmann A; Menjot de Champfleur N; Canioni D; Chandesris O; Costes V; Villain M; Mura F
Optom Vis Sci; 2016 Nov; 93(11):1440-1443. PubMed ID: 27560850
[TBL] [Abstract][Full Text] [Related]
38. [Sudden death in the presence of systemic mastocytosis and urticaria pigmentosa].
Wehner F; Wehner HD; Fritz P; Benz D; Schulz MM
Arch Kriminol; 2008; 222(5-6):187-94. PubMed ID: 19216369
[TBL] [Abstract][Full Text] [Related]
39. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
40. [Systemic mastocytosis].
Niedoszytko M; Lange M; Chelminska M; Jaśkiewicz K; Piskosz A; Wasag B; Lewandowski K; Mital A; Renke J; Gruchała-Niedoszytko M; Woźniak M; Babińska A; Jassem E
Pneumonol Alergol Pol; 2005; 73(3):239-44. PubMed ID: 16989160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
